Biotech Values

[vinmantoo]

Pfizer (NYSE:PFE) has decided not to further develop sisunatovir, an antiviral targeted at respiratory syncytial virus (RSV), which was part of the company's $525M acquisition of privately held ReViral in 2022, Endpoints News reported Tuesday.

According to a federal register on clinical trials, the New York-based pharma giant has discontinued a Phase 2/3 trial and a Phase 1 study for sisunatovir, an oral agent designed to block RSV virus entry to the body.

That should be a positive for ENTA or at worst neutral.